Norland signs new densitometer deal
After terminating a two-year alliance with Canadian firm IMRO, bone densitometry vendor Norland has found a new partner for an ultrasound densitometer unit. The White Plains, NY, company in June acquired rights to distribute and service an ultrasound
After terminating a two-year alliance with Canadian firm IMRO, bone densitometry vendor Norland has found a new partner for an ultrasound densitometer unit. The White Plains, NY, company in June acquired rights to distribute and service an ultrasound bone measurement system developed by U.K. firm McCue.
The June 17 agreement gives Norland the right to distribute McCues CubaClinical system in Canada, parts of Europe, the Middle East, and the Pacific Rim. The company will distribute and service the system in the U.S. once it has received clearance from the Food and Drug Administration, which McCue expects later this year. CubaClinical is a dry system and boasts a large clinical database, according to Norland executives.
Norland signed a deal with IMRO in 1997 for rights to distribute IMROs existing ultrasound bone measurement system, which Norland called Paris (SCAN 2/18/98 and 9/17/97). Norland began shipping Paris to European and Pacific Rim clients last year, but when Paris didnt receive PMA clearance in the U.S. as Norland had expected, the company ended its alliance with IMRO.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
